Aligos TherapeuticsALGS -2.22%37 EV-to-OCF is 0.11 as of Jul. 11, 2026, which is 65% below its 10-year median of 0.31. GuruFocus rates ALGS with a GF Score™ of 37/100 and a GF Value™ of $2.78 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Aligos Therapeutics ranks worse than 73.31% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Aligos Therapeutics's Enterprise Value is $-9.59 Mil.
Aligos Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-84.72 Mil. Therefore, Aligos Therapeutics's EV-to-OCF for today is 0.11.
The historical rank and industry rank for Aligos Therapeutics's EV-to-OCF or its related term are showing as below:
ALGS'
s EV-to-OCF Range Over the Past 10 Years
Min: -12.62 Med: 0.31 Max: 1.2
Current: 0.11
During the past 8 years, the highest EV-to-OCF of Aligos Therapeutics was 1.20. The lowest was -12.62. And the median was 0.31.
ALGS's EV-to-OCF is ranked worse than 73.31% of 1409
companies
in the Biotechnology industry
Industry Median: -3.52
vs ALGS: 0.11
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aligos Therapeutics's PE Ratio (TTM) for today is calculated as:
Aligos Therapeutics's share price for today is $6.63.
Aligos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.690.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aligos Therapeutics EV-to-OCF Related Terms
Aligos Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Aligos Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aligos Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's EV-to-OCF falls into.
Aligos Therapeutics's current Enterprise Value is $-9.59 Mil.
Aligos Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-84.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aligos Therapeutics (ALGS) has a EV-to-OCF of 0.11 as of Jul. 11, 2026. This is 65% below median its historical median of 0.31. According to the industry distribution chart, Aligos Therapeutics ranks #1033 out of 1409 companies in the Biotechnology industry, placing it in the top 73.3%.
Is Aligos Therapeutics' EV-to-OCF too high?
Aligos Therapeutics' current EV-to-OCF of 0.11 is 65% below median its 10-year median of 0.31. Based on the distribution chart, Aligos Therapeutics ranks #1033 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aligos Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' EV-to-OCF compare to SNTI and NTRB?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #1033 out of 1409 companies for EV-to-OCF. This places Aligos Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Aligos Therapeutics's current EV-to-OCF is 0.11, which is 65% below median its own 10-year median of 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.78, compared to a current price of $6.63 — trading 138.5% above its estimated fair value. The current EV-to-OCF is 0.11, which is 65% below median its 10-year median of 0.31. Aligos Therapeutics' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current EV-to-OCF is 0.11 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (ALGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued.
The current stock price of $6.63 is trading 138.5% above its estimated GF Value™ of $2.78.
GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.
Key valuation signals for ALGS:
EV-to-OCF: 0.11 (65% below median its 10-year median of 0.31)
GF Value™: $2.78 vs. price of $6.63 (138.5% above fair value)
No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
37GF Score
Get the complete analysis for ALGS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALGS has been successfully added to your 
